How taladegib works in healthy volunteers
Treatments studied
Part of Lungs & breathing clinical trials.
This trial is for healthy volunteers to see how the study drug taladegib (ENV-101) interacts with other medicines in the body. It will help researchers understand how the drug is absorbed and processed, which is important for future studies in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult, 18 years or older, with no significant medical problems.
- Your body mass index (BMI) must be between 18.5 and 32, and you must weigh at least 110 lbs (50 kg).
- You cannot take any prescription or over-the-counter medications (including vitamins) for a period before and during the study.
- You must not smoke or use any nicotine products (cigarettes, vaping, gum, patches) for at least 3 months before the study starts.
- You must be willing to stay at the study site for the required isolation period (several days to weeks) and follow the study diet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study tests a new oral medication in healthy men to see how the body absorbs, processes, and eliminates it. It's an early step to determine safety and dosing, and you would be closely monitored.
This trial tests an oral medication, ifetroban, to see if it can slow the progression of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to improve breathing and lung function in patients with IPF.
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
This trial tests a new extended-release medicine, nalbuphine, to reduce chronic coughing in people with idiopathic pulmonary fibrosis (a lung disease that scars the lungs). It may help make cough less frequent and less bothersome.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.